A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure
Public ClinicalTrials.gov record NCT06299826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIb Two-Cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients With Chronic Heart Failure
Study identification
- NCT ID
- NCT06299826
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 375 participants
Conditions and interventions
Conditions
Interventions
- AZD5462 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 3, 2024
- Primary completion
- Feb 9, 2026
- Completion
- Feb 9, 2026
- Last update posted
- Jul 7, 2026
2024 – 2026
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Alexander City | Alabama | 35010 | — |
| Research Site | Northridge | California | 91325 | — |
| Research Site | Torrance | California | 90502 | — |
| Research Site | Vista | California | 92081 | — |
| Research Site | Miami | Florida | 33133 | — |
| Research Site | Miami Beach | Florida | 33140 | — |
| Research Site | Richmond | Indiana | 47374 | — |
| Research Site | Boston | Massachusetts | 02114 | — |
| Research Site | Buffalo | New York | 14215 | — |
| Research Site | Rosedale | New York | 11422 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Knoxville | Tennessee | 37916 | — |
| Research Site | Manassas | Virginia | 20109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06299826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 7, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06299826 live on ClinicalTrials.gov.